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Summary
Coronary risk assessment in asymptomatic subjects is
an important issue in primary care. Global coronary
risk assessment has been incorporated in recent guide-
lines (www.agla.ch) and clearly defines, which step
should be taken in relation to risk stratification ob-
tained from coronary risk charts. However, silent myo-
cardial ischaemia is encountered quite frequently and
such subjects probably are at higher risk than derived
from coronary risk charts. Silent ischaemia can be de-
tected by several methods: exercise electrocardiogram
(ECG), stress imaging studies (stress echocardio-
graphy, stress myocardial perfusion SPECT, stress
myocardial perfusion PET, stress magnetic resonance)
or Holter monitoring. Increasing evidence suggests
that coronary revascularisation of asymptomatic is-
chaemia with known CAD improves prognosis, how-
ever, in primary care subjects with silent ischaemia
and under optimal medical treatment, revascularisa-
tion does not improve outcome. In the future it may
prove to be important to define categories of asympto-
matic patients who might nevertheless benefit from
ischaemia testing. Numerous studies have shown that
an aggressive medical therapy in asymptomatic
subjects with high coronary risk reduces global plaque
burden, myocardial ischaemia and coronary events.
“Negative” ischaemia tests in the setting of high coro-
nary risk may even deter primary care physicians from
aggressive primary prevention. Therefore, at the mo-
ment, ischaemia tests are neither recommended in
asymptomatic primary care patients nor in the gene-
ral population; but adherence to preventive guidelines
is fundamentally important to reduce the epidemic of
coronary artery disease.
Key words: coronary heart dis-
ease; primary care; prevention
Introduction
Should tests that detect myocardial ischaemia be used
to identify asymptomatic subjects at high cardiovascu-
lar risk? Might myocardial ischaemia tests extend or
even replace conventional risk factor assessment and
global risk charts? Is the risk in subjects without is-
chaemia low enough to defer intensive medical primary
prevention therapy despite high coronary risk derived
from risk charts? Will serial ischaemia tests help to
guide the intensity of medical therapy in primary care?
Answers to these questions are important, since
pre- and in-hospital mortality of a first myocardial in-
farction are as high as 23% (17–29%) and 16% (13–
19%) respectively in large historical series of untreated
subjects [1] with a very high subsequent all-cause and
vascular mortality rate (up to 10% in the first year).
Further, the epidemic of diseases caused by coronary
atherosclerosis is a long way from being under control
[2].
Performing ischaemia tests in the healthy, asymp-
tomatic general population or in the setting of primary
care in order to detect and treat coronary artery dis-
ease before the occurrence of myocardial ischaemia,
cardiac death, or myocardial infarction, is not estab-
lished. However, in certain subsets of risk subject, is-
chaemia testing might be useful to improve outcome.
In this review we discuss the possible value of myo-
cardial ischaemia tests in the general population and
in various subsets of the population, e.g., in subjects
with a high coronary risk score, severe atherosclerosis
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defined by atherosclerosis imaging, in subjects with
dyspnoea or in subjects with diabetes mellitus.
Detection of ischaemia using exercise ECG or
Holter monitoring in the healthy, asymptomatic
population
In an overview study including over 10000 healthy
subjects participating in prevention trials (Seattle
Heart Watch study, Lipid Research Clinics Program,
United States Air Force personnel, Norwegian office
workers, Indiana State Police employees), a pathologi-
cal exercise ECG test was documented in 5% of the sub-
jects [3]. Coronary artery disease (CAD) was confirmed
subsequently by a coronary angiography in 2.5% (speci-
ficity of the exercise ECG in this population: 50%).
Therefore, the prevalence of silent CAD in this large
group of subjects was low and the absence of silent
CAD as measured by the exercise ECG was present in
as many as 9750 subjects which makes cost-efficiency
of such unrestricted testing very questionable [3]. Al-
though the relative risk of death per year was in-
creased 10-fold in subjects with a pathological exercise
test, absolute annual mortality was relatively low in
both groups (0.7% per year in subjects with ischaemia
on a stress ECG vs 0.07% in those subjects without
ECG defined ischaemia). However, in selected patients,
untreated silent ischaemia on a stress ECG was found
to be related to an all cause mortality of 1.4% per year
and 0% if patients were managed with an additional
intensive antiischaemic drug therapy [4].
A Holter ECG monitoring study revealed that the
prevalence of silent ischaemia in a healthy, asympto-
matic population may increase with age and may be as-
sociated with a >4-fold increase for coronary events [5].
However, the majority of events occurred in subjects
without evidence of ischaemia in this Holter monitor-
ing study, highlighting the problem of its low sensitiv-
ity for detecting silent ischaemia in asymptomatic sub-
jects and thereby preventing serious cardiac events [5].
Recently, the U. S. Preventive Services Task Force
published a review on exercise ECG testing as a screen-
ing tool for CAD [6]. This Task Force aimed to answer
the question, whether such tests add incremental in-
formation. The Task Force concluded, that “although
screening exercise tolerance testing detects severe coro-
nary artery obstruction in a small proportion (<2.7%) of
persons screened and can provide independent prog-
nostic information about the risk of coronary heart dis-
ease events, the effect of this information on clinical
management and disease outcomes in asymptomatic
patients is unclear.” Similar conclusions were made in
a recent statement by the American Heart Association
[7].
Other parameters derived from the exercise ECG,
such as heart rate recovery (HRR) and exercise capac-
ity expressed as metabolic equivalents (MET) have
been proposed as additional factors for identifying high
risk subjects classified as intermediate risk by the
Framingham risk scores [8]. In a long-term cohort
study with over 20-years observation time in which
3329 men and 2797 women, 25% of men had an inter-
mediate Framingham risk score (FRS 10–19%) and 7%
of women had a low to intermediate FRS (6–19%). In
those found to have a low HRR/MET, 50% were shifted
into the high risk category. The cardiovascular death
rate over 10 years for these patients was 8.3% in men.
In women, the observed cardiac death rate was even
higher: 10.8% in women with FRS of 6–9% and 18.5%
in those with a baseline of FRS of 10–19%. Therefore,
a strategy of “sequential testing” could potentially iden-
tify subjects at intermediate risk based on FRS and at
high risk based on the combination of FRS and
HRR/MET.
In summary, exercise testing in asymptomatic sub-
jects is not accepted or recommended in the current
guidelines. More observational data are needed to
clearly identify the benefit of exercise testing in asymp-
tomatic, healthy individuals. An important role of ex-
ercise testing appears to be the stratification of inter-
mediate risk subjects, however, further studies are
needed in the absence of sufficient evidence.
Ischaemia testing with imaging techniques
(ECHO, SPECT, MRI) in high-risk asymptomatic
subjects
Silent myocardial ischaemia (i.e. ischaemia causing no
symptoms) has a poor prognosis in patients after myo-
cardial infarction [9, 10] or in diabetic subjects [11].
In patients without known prior coronary artery dis-
ease (CAD), the prevalence of silent CAD (defined by a
coronary stenosis of >50%) is 2.5–11% in non-diabetic
patients as compared to 6.4–23% in low-risk diabetic
patients [12, 13]. More importantly, diabetic patients
without documented CAD have the same prognosis as
non-diabetic patients with manifest CAD placing dia-
betic patients directly in the high-risk group. The prog-
nosis of diabetic patients worsens dramatically once
they develop manifest CAD. It is therefore important to
treat all diabetic patients as aggressively as patients
with manifest CAD and without further risk stratifi-
cation.
In CAD, chest pain or angina represent only the
“tip of the iceberg” [12, 13]. Several steps precede the
onset of angina. The decrease of perfusion is the first
step of the cascade and perfusion is reliably visualized
e.g., by nuclear cardiology methods (MPS and Positron
Emission Tomography [PET]).
There are several subsets of subjects with a higher
potential for silent ischaemia: e.g., subjects with a
>20% risk for a heart attack based on risk charts (e.g.,
PROCAM or NCEP III), subjects with subclinical ath-
erosclerosis as evidenced non-invasively by atheroscle-
Kardiovaskuläre Medizin 2009;12(12):327–332
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rosis imaging, subjects with dyspnoea or subjects with
diabetes mellitus.
No proven benefit of ischaemia imaging testing
in subjects defined at high risk by risk charts,
atherosclerosis imaging or subclinical athero-
sclerosis by coronary angiography
Non significant coronary atherosclerosis (e.g., stenosis
<50%) is viewed as a benign condition, even when un-
treated. Based on large historical cohorts observed in
the pre-aspirin period (before 1980, fig. 1), the absence
of signs of atherosclerosis on a coronary angiography
was related to an excellent survival with an annual
mortality of 0.6% [14]. However, in subjects with some
subclinical atherosclerosis, a so called “near-normal”
coronary angiogram, mortality was nearly doubled at
1.1% per year. Vascular risk of death higher than 5% in
10 years or 0.5% per year has been defined a high risk
situation by the European Score guidelines [15]. There-
fore, an annual mortality of 1.1% year is not a low risk
situation in subjects with a “near normal” coronary an-
giogram. Surprisingly, in this historical pre-aspirin and
pre-statin cohort of the CASS registry, subjects with
angiographically documented CAD (luminal narrowing
>50%), angina Class I and II and preserved left ven-
tricular function (LVEF >50%) had an annual mortal-
ity rate of 1.0% in single vessel disease, of 1.2% in dual
vessel disease and of 1.4% in triple vessel disease [16].
Therefore, “natural course” mortality risk in subjects
with “near normal”, non obstructive CAD is similar to
subjects with preserved left ventricular function and
single or dual vessel disease, if anginal symptoms are
not severe (Class I and II). Further, based on another
historical observation, the annual risk for fatal or non-
fatal myocardial infarction was 1.2% annually in sub-
jects with coronary luminal narrowing between 25–
50% as opposed to 0.3% annually in subjects with co-
ronary stenoses <25% [17]. Therefore, in terms of heart
attack risk defined by the cardiovascular Munster
(PROCAM) study [18], “near normal” angiography may
infer at least an intermediate risk for myocardial in-
farction. Therefore, the argument, that the detection of
clinically silent atherosclerosis with outward remodel-
ling of coronary plaques and compensatory enlarge-
ment of the coronary arteries – the so-called Glagov
phenomenon [19] – may be important. In fact, high risk
defined by major independent cardiovascular risk fac-
tors correlates well with a non-invasively detected
heavy burden of atherosclerosis in coronary and carotid
arteries [20]. This lends support to the concept, that
atherosclerosis imaging may yield additional and in-
dependent information above and beyond risk scores
derived from Framingham, PROCAM or SCORE. Im-
portantly, most subjects with subclinical atherosclero-
sis have cardiovascular risk factors and should be
treated accordingly. Ischaemia imaging tests in these
subjects are very likely to show normal results and re-
sult in false reassurance.
Further, there are no scientific data that have ad-
dressed the question, whether routine testing using
stress echocardiography, stress myocardial perfusion
studies (SPECT) or stress cardiovascular magnetic res-
onance (CMR) would help to reduce event rates for myo-
cardial infarction in asymptomatic subjects with a
high risk based on risk charts, e.g., PROCAM. The
same is true for subjects with high risk findings based
on atherosclerosis imaging, e.g., extensive coronary cal-
cifications. Although subjects with a coronary calcium
score (Agatston Score) over 400 were shown to have
silent ischaemia on an exercise SPECT study in 40% of
cases [21], there is still a lack of proof, that these 40%
with ischaemia and severe and extensive coronary cal-
cifications have a higher risk for subsequent myocar-
dial infarction than those with severe and extensive
coronary calcifications, but without ischaemia. Further,
we do not know, if medical intervention following this
kind of sequential testing (e.g., first coronary calcium
score testing, then second, SPECT testing, only if se-
vere and extensive coronary calcifications are present)
would reduce the risk for heart attacks in these pa-
tients.
A still experimental but promising ischaemia test-
ing tool is adenosin cardiovascular magnetic resonance
(CMR). So far the largest multicentre study comparing
this method with invasive coronary angiography and
stress SPECT found a higher diagnostic accuracy to de-
tect stenoses >50% for adenosin-CMR than for stress
SPECT: using ROC analysis, adenosin-CMR had a
value of 0.86 versus 0.67 for stress SPECT (p <0.01)
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Figure 1
Total mortality: risk in relation to coronary atheromatosis and stenosis in historical
patient groups (before 1980) and actual risk for clinical entities (previous vascular
disease or diabetes mellitus type 2) [14–18, 32, 39, 41].
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[22]. Another potential advantage of adenosin-CMR is
the complete absence of irradiation. However, in view
of the very low event rate of 0.6% per year with stress
SPECT, the higher sensitivity of adenosin-CMR may
not translate into a better outcome, if such patients
with a normal stress SPECT, but an abnormal
adenosin-CMR are revascularised. Further, in subjects
able to exercise physically, pharmacological stress tests
are neither indicated [7] nor do they in general allow
detection of exercise induced endothelial vasomotor
dysfunction, subclinical atherosclerosis and subsequent
exercise induced coronary artery spasm [23]. Therefore,
adenosin CMR is still reserved for experienced and spe-
cialised centres in symptomatic subjects with clinical
suspicion of CAD who are unable to perform a regular
exercise stress test.
In summary, it is generally not recommended to
perform ischaemia tests in asymptomatic high-risk
subjects defined by risk scores or atherosclerosis imag-
ing. However, intensive primary prevention therapy is
certainly needed in all these cases.
Is there an additive value of ischaemia imaging
in subjects with diabetes mellitus or exercise
induced dyspnoea?
The relatively high prevalence of silent CAD in partic-
ular in the diabetic patient stresses the fact that prog-
nostic considerations of this problem are of potential
prognostic benefit.
Myocardial perfusion SPECT (MPS) is a widely
used cardiac imaging tool to detect CAD in sympto-
matic subjects. Its diagnostic and prognostic value has
been demonstrated by a huge amount of evidence [12,
24–32]. MPS has excellent sensitivity and good speci-
ficity in the detection of CAD, 87% and 73%, respec-
tively [33], as shown by a pooled analysis evaluating
over 4000 patients. Patients with a normal MPS and
normal left ventricular ejection fraction, in general
have an excellent prognosis, with a cardiac death or
myocardial infarction rate of less than 1% [34–36], even
in the presence of CAD.
To date, there are several retrospective studies, but
only one study that has prospectively evaluated the
prevalence of silent CAD in diabetic patients. Wackers
et al. conducted the Detection of silent myocardial Is-
chaemia in Asymptomatic Diabetic subjects (DIAD)
study [37, 38]. 522 patients were screened by MPS. Of
these, 22% had an abnormal stress test result. Cardiac
autonomic neuropathy turned out to be the only inde-
pendent predictor of abnormal MPS – none of the well-
known CAD risk factors.
Rajagopalan et al. examined angiographic findings
and mortality rates in 826 asymptomatic diabetic pa-
tients with respect to MPS findings [39, 40]. The mor-
tality rate was 5.9% in high-risk patients, 5.0%, in in-
termediate-risk patients and patients 3.6% in low-risk
(p <0.001 for differences between groups). Post hoc
analyses were performed to determine if a truly low-
risk (annual mortality <1%) subset of patients could be
identified. Annual mortality in diabetic patients with-
out Q-wave myocardial infarction at ECG, without pe-
ripheral arterial disease, and with a completely normal
SPECT imaging scan (n = 443), was only slightly lower
but at 2.9%. The annual mortality rate was higher in
patients with preoperative versus other indication for
MPS evaluation (5.9% vs 2.7%; p <0.001). The annual
mortality rate for patients without a preoperative in-
dication whose scan was normal (n = 298) amounted to
1.9%. For patients without a preoperative indication,
Q-waves, or peripheral arterial disease, the annual
mortality rate was 1.6% for those with a normal scan
(n = 237) and 3.4% for those with a high-risk scan (n =
79). Importantly, although a normal MPS study is gen-
erally associated with a low risk (<1% annual risk of
cardiac death or myocardial infarction), the challenge
in a diabetic population is to define the elusive “low-
risk” patient. To date, reports have consistently shown
that normal MPS in diabetic populations is not associ-
ated with this low level of risk and, in direct compar-
isons, patients with diabetes are at significantly
greater risk than non diabetics with normal MPS [11,
32, 39, 41, 42]. Similarly, in the setting of an abnormal
MPS, the risk conferred by any given extent and sever-
ity of perfusion abnormality is greater in patients with
diabetes than in non diabetics. Zellweger et al. as-
sessed the incidence of MPS evidence of CAD in dia-
betic patients without known CAD and the impact of
symptoms and scintigraphic findings on prognosis [32].
Objective evidence of CAD was found in 39% of 826
asymptomatic diabetic patients, in 51% of 151 diabetic
patients with shortness of breath, and in 44% of 760 di-
abetic patients with angina. Overall, patients with a
normal MPS had quite a good prognosis irrespective of
symptomatic status, although the mortality was not
<1%. Patients with an abnormal MPS had a signifi-
cantly worse outcome. Of note, there was no prognostic
difference in patients with abnormal MPS when
asymptomatic patients and those with angina were
compared.
In contrast, patients with shortness of breath had
a very high event rate, reflecting in part that these pa-
tients had more often suffered a silent myocardial in-
farction than asymptomatic patients and those with
angina. In the multivariate Cox proportional hazards
model, age, hypertension, shortness of breath, extent
of scarring, and extent of ischaemia were independent
predictors of events. Hypercholesterolaemia and family
history of CAD tended to be independent predictors of
events [43]. Of note, angina was not a significant pre-
dictor of critical events in this model, but shortness of
breath was. MPS added incremental information to
clinical and prescan information to predict the outcome
(fig. 2).
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In summary, in asymptomatic high risk subjects as
defined by high risk scores (i.e. subclinical atheroscle-
rosis or diabetes mellitus) under optimal medical treat-
ment, there is no proof until today, that the addition of
highly technological ischaemia tests will improve out-
come [44]. The worst case scenario is that high-risk
subjects with a “negative” ischaemia test might not re-
ceive adequate aggressive preventive therapy. In fact,
the recently published DIAD study [45] assessed the
impact of myocardial perfusion SPECT in 1123 diabetic
subjects (mean age 61 years, mean duration of diabetes
mellitus 8 years) randomised to ischaemia screening or
usual care. The 5 year rate of myocardial infarction and
cardiac death (MACE) could not be positively influ-
enced by the ischaemia screening strategy, in that both
groups had a low risk for MACE at 5 years of follow up
(2.7% in the screening and 3.0% in the non screening
group, p not significant). However, during the course of
study there was a significant and equivalent increase
in primary medical prevention in both groups. This un-
derscores again the importance of treating – and not
imaging – high risk subjects in order to reduce risk.
However, subjects with exercise induced dyspnoea
should be submitted to a thorough medical investiga-
tion in order to identify treatable causes.
Conclusions
Coronary risk in the asymptomatic population is best
assessed and treated according to coronary risk charts
(e.g., PROCAM) and guidelines even in asymptomatic
subjects with proven coronary artery stenosis [9].
ACC/AHA/ASNC Guidelines for the “Clinical Use of
Cardiac Radionuclide Imaging” made a clear statement
about testing asymptomatic patients [33]: The rela-
tively low prevalence of CAD and risk of future events
will affect the performance of any diagnostic test in a
manner predictable by Bayesian principles (e.g., posi-
tive predictive value will usually be low). It is not clear
that detecting asymptomatic preclinical CAD will lead
to therapeutic intervention and reduce risk beyond
that indicated by risk factor profiling and currently rec-
ommended strategies in reducing risk. Persons whose
occupations may affect public safety (e.g., airline pilots,
truck-drivers, bus drivers) or who are professional or
high-profile athletes commonly undergo periodic exer-
cise testing for statutory reasons. Currently, there are
no existing guidelines saying, that ischaemia testing
may be appropriate when there is a high-risk clinical
situation (e.g., diabetes mellitus or multiple risk fac-
tors).
The question of therapeutic approaches in silent
CAD is an important topic for ongoing debate. The data
dealing with this issue are scarce and further studies
are underway.
It is also likely that rigorous primary prevention
by risk factor modification and treatment (e.g., lipid
lowering with statins) will lead to improvement of per-
fusion and thus to regression of CAD in asymptomatic
patients with evidence of silent CAD.
In summary, the key message of this review is sim-
ple. High risk subjects (diabetes, several cardiovascu-
lar risk factors) should be treated maximally in pri-
mary care. This is the only proven strategy preventing
organ damage due to atherosclerosis and emphasises
the eminent importance of family doctors in the pro-
tection of their patients. Subjects with exercise induced
dyspnoea need a medical work up in order to identify
the cause of this high risk clinical condition. Ischaemia
tests are not a treatment, are not infrequently normal
despite a high risk situation and may detract physi-
cians from treating their patients correctly. More stud-
ies however are needed in order to clarify the advan-
tage of ischaemia tests to identify undetected CAD,
since these subjects may benefit from coronary revas-
cularisation in an additive way, on top of vigorous risk
factor treatment.
The coexistence of diabetes and previous cardio-
vascular disease infers highest risk to these patients
(fig. 1). These patients benefit the most from aggres-
sive risk lowering medical intervention.
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